Zampilimab (UCB7858) | UCB
UCB's Global Corporate Website

Zampilimab (UCB7858)

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Chronic Allograft Injury A 2-Stage, Multicenter, Randomized, Placebo-Controlled Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury Phase1/2 CAI001
Terminated
NCT04335578
2017-004807-31